Rifaximin for Treatment of Small Bowel Bacterial Overgrowth
Journal Title: Current Trends in Gastroenterology and Hepatology - Year 2018, Vol 1, Issue 3
Abstract
Small intestinal bacterial overgrowth (SIBO) is often secondary to intestinal dysmotility and several other predisposing conditions. Treatment of SIBO typically includes antibiotics and treatment of underlying etiology. Identification and treatment of the underlying modifiable causes is critical for management of refractory and recurrent SIBO. We report here a case of scleroderma with small bowel dysmotility and bacterial overgrowth, on different occasions the patient failed to respond to Rifaximin. We showed that restoring small bowel motility is critical in maintaining the effectiveness of Rifaximin in the treatment of SIBO. Rifaximin resistance may also develop following prolonged use of antibiotics. Rotation of antibiotic regimen is important to prevent drug resistance.
Authors and Affiliations
Dabo Xu, Chung Owyang
Keywords
Related Articles
- EP ID EP570009
- DOI 10.32474/CTGH.2018.01.000115
- Views 49
- Downloads 0
Asymptomatic Portal Cavernoma Revealing Activated Protein C Resistance
Introduction: Unlike the child, the portal cavernoma (PC) remains an exceptional and unusual complication of portal thrombosis in adults and the elderly. We report an original observation of asymptomatic PC secondary to...
Utilization of Traditional Anticoagulation for Venous Thromboembolism in Patients with Liver Cirrhosis: Is It Safe?
Patients with liver cirrhosis are known to have increased risk bleeding particularly from gastrointestinal tract. However, recent literature has shown that patients with liver cirrhosis are also at increased risk of deve...
Utilization of Direct Acting Oral Anticoagulants in Patients with Liver Cirrhosis: Is It Safe?
Patients with liver cirrhosis are known to have increased risk of bleeding particularly from gastrointestinal tract. However, recent literature has shown that patients with liver cirrhosis are also at increased risk of t...
Advanced Hepatocellular Carcinoma in A Scottish Population – Current Experience and the Future
Sorafenib is the current first line standard of care in patients with advanced hepatocellular carcinoma (HCC). Several other drugs are emerging as efficacious agents in this setting. This article will outline our current...
Reproductive Health and Fertility in Transition Clinic for Liver Transplant Patients
The transition of an adolescent into adulthood is fraught with complexity under the best of circumstances. Misinformation or a lack of medical knowledge during this critical time can place young adults in a position to d...